We are live on ! Find out more
IBBJ

Defiance Nasdaq Junior Biotechnology ETF

Delisted

IBBJ was delisted on the 2nd of December, 2021.

9 hedge funds and large institutions have $761K invested in Defiance Nasdaq Junior Biotechnology ETF in 2021 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding

Funds holding: 69 (+3)

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

36% less capital invested

Capital invested by funds: $1.19M → $761K (-$433K)

Holders
9
Holders Change
+3
Holders Change %
+50%
% of All Funds
0.16%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
3
Reduced
3
Closed
Calls
Puts
Net Calls
Net Calls Change

IBBJ Hedge Fund Activity: Q1 2021 in Review

9 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Defiance Nasdaq Junior Biotechnology ETF (IBBJ) for Q1 2021, worth a combined $761K — down 36% from $1.19M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new IBBJ positions and 0 closed out — a net gain of 3 holders — while 3 added to existing stakes and 3 trimmed.

The largest buyer was RMR Wealth Builders, adding an estimated $39.9K. The largest seller was Tower Research Capital (TRC), cutting an estimated $527K.

  • 9 institutional investors held Defiance Nasdaq Junior Biotechnology ETF (IBBJ) as of Q1 2021, up from 6 in Q4 2020.
  • Funds reported $761K of Defiance Nasdaq Junior Biotechnology ETF stock for Q1 2021, down 36% quarter-over-quarter.
  • 3 funds opened new Defiance Nasdaq Junior Biotechnology ETF positions in Q1 2021 and 0 closed out, a net change of +3 holders.
  • The largest Defiance Nasdaq Junior Biotechnology ETF buyer in Q1 2021 was RMR Wealth Builders, an estimated $39.9K added.
  • The largest Defiance Nasdaq Junior Biotechnology ETF seller in Q1 2021 was Tower Research Capital (TRC), an estimated $527K sold.

Based on aggregated 13F filings for Q1 2021.